Bristol/AstraZeneca Roll Out Onglyza Post-Market Cardio Study
This article was originally published in The Pink Sheet Daily
Executive Summary
The Phase IV commitment to study cardio risk is part of saxagliptin's approval, but the partners are also looking for data to support a claim of cardioprotective effect.
You may also be interested in...
Bristol-Myers Sees Five Meds Cushioning The Fall Off The Patent Cliff
Just two days after being named the next chief executive officer at Bristol-Myers Squibb, Lamberto Andreotti told a crowd of Wall Street analysts that the drug maker is on track to launch five medicines by 2012 - the year two key drugs go off patent - and vowed that strong financial growth will resume by 2014
Avandia Advisory Cmte. Is FDA's Primary Response To Congressional Pressure
Sponsors will get another look in July at how FDA interprets guidance for assessing the cardiovascular risk of diabetes drugs in clinical trials. The venue will be a meeting of the Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees
FDA Clears Victoza, But Warnings And More Studies Pose Hurdles
Liraglutide's US approval comes with a black box warning for a thyroid cancer risk and hefty post-marketing requirements.